France is expanding access to weight-loss medications under its national health system, marking a major shift in how the country addresses obesity—a chronic condition affecting nearly 17% of adults, according to public health data. Starting this month, two prescription drugs, semaglutide and liraglutide, will be covered for patients with a body mass index of 30 or higher, or 27 with obesity-related complications like type 2 diabetes or severe sleep apnea.
Why it matters
This policy change comes as obesity rates climb globally, with France ranking among the top European nations for severe obesity. The decision follows years of debate over whether weight-loss drugs—once reserved for extreme cases—should become a standard tool in public health. Experts say the move could reduce long-term healthcare costs by preventing obesity-linked diseases like heart disease and joint problems.
How the drugs work and who qualifies
The two approved medications, semaglutide (marketed as Wegovy) and liraglutide (Saxenda), mimic a hormone that regulates appetite and slows digestion. Clinical trials have shown they can help patients lose 10–15% of their body weight over a year, though side effects like nausea and digestive issues are common.
Eligibility is tied to BMI thresholds and comorbidities. A 2023 study published in The Lancet found that patients with a BMI over 30 who used these drugs for two years had a 40% lower risk of developing type 2 diabetes compared to those on placebo. However, coverage will initially apply only to patients under 65, with older adults evaluated on a case-by-case basis.
Reactions from clinicians and health officials
Dr. Élodie Bouvet, an endocrinologist at the Paris Public Health Agency, called the decision “a necessary step toward treating obesity as a serious medical condition, not just a lifestyle issue.” She noted that while drugs are effective, they work best when combined with diet and exercise. “We’re not advocating for a pill-only solution,” she said.
Critics, including some nutritionists, argue the move could divert attention from broader public health strategies like food policy reforms. “Medications alone won’t solve France’s obesity epidemic,” said Sophie Martin, a public health researcher at the University of Bordeaux. “We still need better access to affordable, healthy food and school nutrition programs.”
Limitations and unanswered questions
Several key uncertainties remain. Long-term data on whether weight loss is sustained beyond two years is limited, and studies on children or adolescents are still ongoing. Additionally, the French health system will monitor real-world outcomes closely, with potential adjustments if side effects or cost concerns arise. The drugs themselves cost between €100–€150 per month, but the government estimates the savings from preventing obesity-related illnesses will offset this over time.
Patients will need a doctor’s referral and must meet strict criteria, including failing to lose weight through conventional methods. The policy does not yet cover newer, more expensive medications like tirzepatide (Mounjaro), which has shown even greater weight loss in trials but is not yet approved for obesity treatment in Europe.
What’s next for obesity treatment in France
Health officials plan to review the program’s effectiveness in 18 months, with possible expansions to include more medications or lower BMI thresholds if data supports it. Meanwhile, advocacy groups are pushing for similar coverage in other European countries, where obesity-related healthcare spending is projected to rise by 25% by 2030.
For now, the focus remains on balancing access with sustainability. As one official put it: “This is about giving patients tools they’ve been denied for too long—but it’s not a silver bullet.”
